|Epigenomics AG -- USA Stock|| |
USD 4.55 0.12 2.71%
COO and Member of Executive Board
Dr. Uwe Staub resigned as Chief Operating Officer at Epigenomics AG with effect from March 31, 2018, a position he has held since April 1, 2013. Prior to that, he served as Senior Vice President Research and Development Manufacturing of the Company from November 1, 2008. He was also granted procura and will take over the responsibility for medical affairs and customer support of the Company. Before joining the Company, Dr. Staub worked 14 years in the IVD industry for Abbott Diagnostics, Digene and Qiagen and gained experience in Operations, Quality and Regulatory Affairs as well as Product Development. He studied Biology at the JuliusMaximiliansUniversitaet Wuerzburg, Germany, and earned his Ph.D. degree in Biochemistry and Human Genetics.
COO Since 2013 Ph.D
49 30 243 450 http://www.epigenomics.com
The company has return on total asset (ROA)
of (44.29) %
which means that it has lost $44.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (122.69) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 607.04 K in total debt with debt to equity ratio (D/E) of 5.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Epigenomics AG has Current Ratio of 1.92 which is within standard range for the sector.
Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany and internationally. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics AG is traded on OTC Market in USA.Epigenomics AG (EPGNF) is traded on OTC Market in USA. It is located in Geneststrasse 5 and employs 43 people.
Epigenomics AG Leadership Team
|Antje Zeise, Executive|
|Guenther Reiter, Executive|
|Gregory Hamilton, CEO, MBA|
|Ann Kessler, Executive|
|Heino Prondzynski, Chairman|
|Helge Lubenow, Executive, Ph.D|
|Thomas Taapken, CEO|
|Annett Dietrich, Executive|
|Noel Doheny, CEO|
|Uwe Staub, COO, Ph.D|
|Albert Weber, SVP|
|Nicola HennebergBusse, President|
|Jorge Garces, President, MBA|
|Nicholas Potter, Director|
|Peter Vogt, Executive|
Stock Performance Indicators
Macroaxis portfolio users are insensible in their opinion about investing in Epigenomics AG. What is your opinion about investing in Epigenomics AG? Are you bullish or bearish?
The main assumption in equity investing is that a higher degree of volatility (or risk) means a higher potential (or expected) return on investment. Conversely, investors who take on a low degree of risk have a low expection for return.
You can create optimal portfolios in USA market or optimize your existing portfolio in one of two ways: 1)
For any level of risk, select the one which has the highest expected return. 2)
For any expected return, select the one which has the lowest volatility.